PRI-724 B

CAS No. 1422253-38-0

PRI-724 B( —— )

Catalog No. M35828 CAS No. 1422253-38-0

PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 112 In Stock
5MG 77 In Stock
10MG 148 In Stock
25MG 264 In Stock
50MG 415 In Stock
100MG 616 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PRI-724 B
  • Note
    Research use only, not for human use.
  • Brief Description
    PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.
  • Description
    PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Wnt/Notch/Hedgehog
  • Target
    Wnt/beta/catenin
  • Recptor
    Wnt/beta-catenin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1422253-38-0
  • Formula Weight
    658.64
  • Molecular Formula
    C33H35N6O7P
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C([C@@H]1N2[C@@](N(C(NCC3=CC=CC=C3)=O)N(C)CC2=O)([C@H](C)N(CC=4C5=C(C=CC4)C=CC=N5)C1=O)[H])C6=CC=C(OP(=O)(O)O)C=C6
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • EMT inhibitor-1

    EMT inhibitor -1 is an inhibitor of Hippo, Wnt signaling and TGF- macrophages (TGF-) with antitumor activity.

  • β-Elemonic Acid

    Beta-Elemonic acid inhibits proliferation by inducing hypoploid cells and cell apoptosis, the anticancer effects of beta-Elemonic acid are related to the MAPK signaling pathway, ROS activation and glutathione depletion in human A549 lung cancer cells.

  • Foxy-5

    Foxy-5 is a novel Wnt-5A mimicking hexapeptide that inhibits breast cancer metastasis in vivo by targeting cell motility.